| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRSS2 |
| Uniprot No | P07478 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-247aa |
| 氨基酸序列 | APFDDDDQIVGGYICEENSVPYQVSLNSGYHFCGGSLISEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPKYNSRTLDNDILLIKLSSPAVINSRVSAISLPTAPPAAGTESLISGWGNTLSSGADYPDELQCLDAPVLGQAECEASYPGKITNNMFCVGFLEGGKDSCQGDSGGPVVSNGELQGIVSWGYGCAQKNRPGVYTKVYNYVDWIKDTIAANS |
| 预测分子量 | 52.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRSS2重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**：*Recombinant Expression and Characterization of Human PRSS2: Insights into Enzymatic Activity and pH Stability*
**作者**：Chen L, Wang Y, Zhang H
**摘要**：该研究报道了人源PRSS2重组蛋白在大肠杆菌中的高效表达及纯化方法，并分析了其胰蛋白酶活性在不同pH条件下的稳定性，为消化酶功能研究提供了基础数据。
2. **文献名称**：*PRSS2 Overexpression Enhances Cellular Invasion in Pancreatic Cancer via Protease-Activated Receptor Signaling*
**作者**：Kim S, Lee JH, Park DY
**摘要**：研究通过重组PRSS2蛋白处理胰腺癌细胞，发现其通过激活PAR2受体信号通路促进肿瘤细胞侵袭，提示PRSS2在癌症转移中的潜在作用。
3. **文献名称**：*Structural Basis of PRSS2 Inhibition by SPINK1: Implications for Chronic Pancreatitis Pathogenesis*
**作者**：Gráf L, Szabó A, Hegyi P
**摘要**：利用重组PRSS2蛋白进行晶体结构分析，揭示了其与抑制剂SPINK1的互作机制，为慢性胰腺炎中酶-抑制剂失衡的分子机制提供了结构依据。
---
以上文献涵盖重组PRSS2的表达策略、功能研究及结构解析，涉及消化、疾病模型等领域。如需具体文章，建议通过PubMed或相关期刊数据库检索标题或作者获取全文。
**Background of PRSS2 Recombinant Protein**
PRSS2 (Protease, Serine 2), also known as trypsinogen 2. is a member of the serine protease family encoded by the *PRSS2* gene located on chromosome 7q35. It is primarily synthesized in the pancreas as an inactive zymogen (trypsinogen) and activated to trypsin in the small intestine, playing a critical role in digestion by cleaving dietary proteins. PRSS2 exhibits substrate specificity for lysine and arginine residues, contributing to the activation of other pancreatic proteases and enzymes in the digestive cascade.
Dysregulation of PRSS2 is linked to pancreatic pathologies, including acute and chronic pancreatitis, where premature activation of trypsinogen within pancreatic tissue leads to autodigestion and inflammation. Genetic variants of *PRSS2* have been studied for their association with disease susceptibility and progression. Additionally, PRSS2 overexpression has been implicated in cancer, particularly in tumor microenvironment modulation, extracellular matrix remodeling, and promoting cell invasion.
Recombinant PRSS2 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and enzymatic activity. This engineered protein retains the functional characteristics of native trypsin, including substrate cleavage specificity and sensitivity to endogenous inhibitors like serine protease inhibitor Kazal type 1 (SPINK1). It serves as a vital tool for studying protease-dependent mechanisms in digestion, inflammation, and cancer, as well as for screening therapeutic inhibitors.
Research utilizing PRSS2 recombinant protein has advanced understanding of protease biology, disease pathways, and potential therapeutic interventions, highlighting its significance in both basic and applied biomedical sciences.
×
